文献速递前列腺癌

低剂量率近距离放疗治疗前列腺癌:>10年随访结局

Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.
PubMed 文献 · BJU Int · 2018-01-30

研究纳入757例1990-2006年接受 definitive LDR-BT 的局限性前列腺癌患者,随访>10年。中位随访12.5年,17年BFFS、DMFS、PCSS、OS分别为79%、97%、97%、72%;生化失败者中82%发生在前10年,18%在>10年后失败。

要点

  • 17年前列腺癌特异性生存率达97%,总生存率72%。
  • 低、中、高危组17年BFFS分别为86%、80%、65%(P<0.001)。
  • 生化失败者中82%发生在头10年,18%在>10年后失败,支持继续随访。

核心结论

  • LDR-BT获得 excellent 生存率,17年PCSS为97%。
  • 生化复发患者中18%在植入>10年后失败, justify 继续随访。

研究设计与样本

  • 回顾性纳入1990-2006年在本机构接受 definitive LDR-BT 的757例局限性前列腺癌患者。
  • 随访>10年,中位随访12.5年(范围10.1-21.8年)。

主要发现

  • 分析时88.6%患者存活,1.5%死于前列腺癌,13.9%出现生化失败,其中82%失败发生在随访头10年。
  • 2.3%出现远处转移。
  • 多因素分析中,T3a-T3b期、PSA>20 ng/mL、中高危疾病预测更差BFFS;诊断时年龄>70岁和T3a-T3b期预测更差OS。
  • 总生物有效剂量≥150 Gy和雄激素剥夺治疗与改善BFFS相关,但与OS无关。
  • 17年BFFS、DMFS、PCSS、OS分别为79%、97%、97%、72%。

临床怎么用

  • LDR-BT后17年PCSS达97%,支持其作为局限性前列腺癌的 definitive 治疗选择。
  • 生化失败可发生在>10年后,对LDR-BT后患者应继续长期随访。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine biochemical control, survival, and late morbidity with definitive low-dose-rate brachytherapy (LDR-BT) for patients with prostate cancer surviving for >10 years after treatment. PATIENTS AND METHODS: We identified 757 men with localised prostate cancer who underwent definitive LDR-BT in the period 1990-2006 and were followed for >10 years at our institution. Biochemical failure-free survival (BFFS), distant metastases-free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS) were selected as study endpoints. Survival was examined using the log-rank test, Kaplan-Meier method, and Cox regression modelling. Urinary, quality of life (QoL), and potency scores at baseline and last follow-up were recorded. RESULTS: The median follow-up was 12.5 years (range, 10.1-21.8 years). At the time of analysis, 88.6% of patients were alive, 1.5% died from prostate cancer and 13.9% developed biochemical failure, with 82% of failures occurring in the first decade of follow-up. Overall, 2.3% developed distant metastases. On multivariate analyses, stage T3a-T3b, prostate-specific antigen level of >20 ng/mL, intermediate- and high-risk disease predicted worse BFFS; whereas age >70 years at diagnosis and stage T3a-T3b predicted worse OS. A total biologically effective dose of ≥150 Gy and androgen-deprivation therapy were associated with improved BFFS, but not OS. The overall 17-year rates for BFFS, DMFS, PCSS, and OS were 79, 97, 97, and 72%, respectively. Respective 17-year BFFS rates for low-, intermediate- and high-risk patients were 86, 80, and 65% (P < 0.001), whereas OS rates for the same groups were 82, 73, and 60%, respectively (P = 0.09). Amongst those patients who were potent at baseline, 25% remained potent at the last follow-up. Urinary function and QoL were mainly unaffected. CONCLUSIONS: LDR-BT yields excellent survival rates, with a 17-year PCSS rate of 97%. In all, 18% of patients with biochemical relapse failed at >10 years after implantation, which justifies their continued follow-up.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lazarev S, Thompson MR, Stone NN, et al. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. BJU Int. 2018. PMID: 29319928. doi:10.1111/bju.14122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。